Compile Data Set for Download or QSAR
Report error Found 7 Enz. Inhib. hit(s) with all data for entry = 10706
TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560832(US11389445, Compound 3 | (R)-2-((1s,4S)-4-(2-methy...)
Affinity DataIC50: 50nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560830(US11389445, Compound 1 | (R)-2-((1s,4S)-4-(6-fluor...)
Affinity DataIC50: 50nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560836(US11389445, Compound 9 | N-(1-((1s,4s)-4-(6-fluoro...)
Affinity DataIC50: 50nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560834(US11389445, Compound 5 | 2-(4-(6-fluoroquinolin-4-...)
Affinity DataIC50: 50nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560833(US11389445, Compound 4 | (R)-N-(4-(pentafluoro-lam...)
Affinity DataIC50: 125nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560831(US11389445, Compound 2 | (R)-2-((1r,4R)-4-(6-fluor...)
Affinity DataIC50: 600nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Beijing Innocare Pharma Tech

US Patent
LigandPNGBDBM560835(US11389445, Compound 8 | (R)-2-((1s,4S)-4-(6-fluor...)
Affinity DataIC50: 600nMAssay Description:The experimental principle is summarized as follows: IDO expression is low in Hela cells under no induction, but a certain concentration of IFN-γ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent